Никита Валерьевич Сурнин
Research Subjects
Никита Валерьевич Сурнин has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Daria I. Kuplevatskaya
Медицинский институт Санкт-Петербургского государственного университета
2 shared publications - Tatyana N. Trofimova
Pavlov First Saint Petersburg State Medical University
2 shared publications - Marlen E. Topuzov
North-Western State Medical University Named After I.I. Mechnikov
1 shared publication - Mikhail A Cherkashin
Diagnostic and Treatment Center of the Sergey Berezin International Institute of Biological Systems
1 shared publication - Mikhail M. Atamas
ФГБОУ ВО СЗГМУ им. И. И. Мечникова
1 shared publication - Nataliya Berezina
Diagnostic and Treatment Center of the Sergey Berezin International Institute of Biological Systems
1 shared publication
Latest Publications
- Open Access
- 15 September 2026
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 72 (4) , 2587
Comparison of MRI Semiology of PI-RADS 3 and PI-RADS 4 Categories with the Results of Stereotactic MRI-Guided Prostate Biopsy
Введение. Рак предстательной железы (РПЖ) – одно из наиболее распространённых онкологических заболеваний у мужчин. Мультипараметрическая МРТ (мпМРТ) позволяет стратифицировать очаги по вероятности клинически значимого РПЖ согласно системе PI‑RADS, однако тактика при PI‑RADS 3 остаётся дискуссионной. Цель. Сопоставить данные МР‑семиотики категорий PI‑RADS 3 и PI‑RADS 4 с результатами стереотаксической (СТ) МР‑направленной биопсии ПЖ. Материалы и методы. Проведён ретроспективный анализ 80 МР‑исследований ПЖ, выполненных в 2019-2024 гг. Оценено 98 таргетных очагов PI‑RADS 3 (n=27) и PI‑RADS 4 (n=71). Всем пациентам выполнена МР‑направленная СТ биопсия под контролем МРТ с последующим гистологическим исследованием. Результаты. Верифицирован РПЖ в 78 из 98 очагов - 79,6% (70,8%; 86,6%). Частота выявления РПЖ составила 48,1% (30,3%; 66,4%) для PI‑RADS 3 и 91,5% (83,4%; 96,4%) для PI‑RADS 4 (p<0,0001). Для PI‑RADS 3 преобладали очаги с Глисон 6 (3+3), тогда как для PI‑RADS 4 – Глисон 7 (3+4). В 44,8% (34,2%; 55,9%) случаев дополнительно выявлен мультифокальный рост вне таргетного очага, при этом степень дифференцировки опухоли в дополнительных очагах рака была аналогичной или выше, чем в установленном таргетном очаге. Медианное значение для размера очага (см3) составило 0,295 (0,13; 0,59), медианное значение для суммы Глисон 7 (6; 7), значимой корреляции между ними не обнаружено (p=0,08). Выводы. Категория PI‑RADS 4 ассоциирована с высокой вероятностью кзРПЖ и требует обязательной таргетной биопсии. При PI‑RADS 3 выполнение биопсии должно определяться индивидуально, с учётом ПСА, возраста и анамнеза. Полученные данные подтверждают ограниченность системы PI‑RADSv2.1 в дифференциации доброкачественных и злокачественных изменений.
- 15 September 2026
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 72 (4) , 2587
Open AccessComparison of MRI Semiology of PI-RADS 3 and PI-RADS 4 Categories with the Results of Stereotactic MRI-Guided Prostate Biopsy
Введение. Рак предстательной железы (РПЖ) – одно из наиболее распространённых онкологических заболеваний у мужчин. Мультипараметрическая МРТ (мпМРТ) позволяет стратифицировать очаги по вероятности клинически значимого РПЖ согласно системе PI‑RADS, однако тактика при PI‑RADS 3 остаётся дискуссионной. Цель. Сопоставить данные МР‑семиотики категорий PI‑RADS 3 и PI‑RADS 4 с результатами стереотаксической (СТ) МР‑направленной биопсии ПЖ. Материалы и методы. Проведён ретроспективный анализ 80 МР‑исследований ПЖ, выполненных в 2019-2024 гг. Оценено 98 таргетных очагов PI‑RADS 3 (n=27) и PI‑RADS 4 (n=71). Всем пациентам выполнена МР‑направленная СТ биопсия под контролем МРТ с последующим гистологическим исследованием. Результаты. Верифицирован РПЖ в 78 из 98 очагов - 79,6% (70,8%; 86,6%). Частота выявления РПЖ составила 48,1% (30,3%; 66,4%) для PI‑RADS 3 и 91,5% (83,4%; 96,4%) для PI‑RADS 4 (p<0,0001). Для PI‑RADS 3 преобладали очаги с Глисон 6 (3+3), тогда как для PI‑RADS 4 – Глисон 7 (3+4). В 44,8% (34,2%; 55,9%) случаев дополнительно выявлен мультифокальный рост вне таргетного очага, при этом степень дифференцировки опухоли в дополнительных очагах рака была аналогичной или выше, чем в установленном таргетном очаге. Медианное значение для размера очага (см3) составило 0,295 (0,13; 0,59), медианное значение для суммы Глисон 7 (6; 7), значимой корреляции между ними не обнаружено (p=0,08). Выводы. Категория PI‑RADS 4 ассоциирована с высокой вероятностью кзРПЖ и требует обязательной таргетной биопсии. При PI‑RADS 3 выполнение биопсии должно определяться индивидуально, с учётом ПСА, возраста и анамнеза. Полученные данные подтверждают ограниченность системы PI‑RADSv2.1 в дифференциации доброкачественных и злокачественных изменений.
- Open Access
- 23 December 2025
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 8 (4) , 60-71
A New Perspective on the Role of MRI in Refining PI-RADS 3 and PI-RADS 4 Categories
Introduction : Prostate cancer (PCa) remains one of the leading causes of cancer-related mortality. Traditional diagnostic methods, including PSA testing and transrectal ultrasound (TRUS), have limitations in detecting early-stage PCa. MRI plays a key role in diagnosis, particularly in identifying clinically significant tumors. However, the PI-RADS v2.1 system has limitations in the quantitative assessment of pathological changes. Purpose : To develop and evaluate quantitative MRI criteria for the differential diagnosis of PI-RADS 3 and PI-RADS 4 lesions, and to identify statistically significant predictors of cancer presence in lesions. Materials and Methods : A retrospective analysis was conducted on 105 patients (aged 49–78 years, median age 65) with suspected PCa from 2019 to 2024. Patients were grouped based on clinical history: negative biopsy (34 %), elevated PSA and negative MRI dynamics (33 %), and rising PSA without ultrasound changes (32 %). Prostate MRI was performed using 1.5 T and 3 T scanners (bi-or multiparametric), with assessment according to PI-RADS v2.1. PI-RADS 4 lesions were identiĮed in 73.3 % of cases, and PI-RADS 3 lesions in 26.7 %. All patients underwent stereotactic MRI-targeted biopsy with sampling from target lesions and systematic biopsy. Statistical analysis included frequency tables, chi-square and Fisher͛ s tests, t-test, Mann–Whitney test, and ROC analysis. Results : PCa was conĮrmed in 78 % of cases (predominantly Gleason 7, ISUP grade 2 adenocarcinomas). PI-RADS 3–4 lesions were most often located in the peripheral zones (73.3 %, posterior regions). New quantitative parameters were introduced: the signal intensity ratio on high b-value DWI (b 1 /b 2 ) and on ADC maps (ADC 2 /ADC 1 ). For all lesions, a b1/b2 threshold х1.56 showed sensitivity of 81.7 % and speciĮcity of 91.3 %; ADC 2 /ADC 1 >2.65 showed 52.4 % sensitivity and 82.6 % speciĮcity. For PI-RADS 4 lesions, thresholds of b1/b2 >1.57 (87.1 % sensitivity, 85.7 % speciĮcity) and ADC2/ADC1 >2.2 (81.4 % and 85.7 %, respectively) were significant predictors of cancer. For PI-RADS 3 lesions, these ratios were not significant. Dynamic contrast enhancement (performed in 34.2 % of cases) helped to reĮne lesion localization but did not influence the biopsy decision; type 3 curves correlated with cancer in PI-RADS 4 lesions (95 %). Discussion : The introduction of quantitative criteria (b 1 /b 2 and ADC 2 /ADC 1 ) allows for a more objective assessment of PI-RADS 4 lesions, reducing the dependence on radiologist experience. These parameters are signiĮcant predictors of clinically significant PCa, particularly in PI-RADS 4. Further research is needed to identify reliable quantitative markers for PI-RADS 3 lesions. Biparametric MRI (without contrast) was suĸcient for biopsy decision-making in most cases (65.7 %), making the method more accessible and safer. Quantitative analysis may assist in selecting between bi- and multiparametric MRI protocols. Conclusion : MRI with quantitative assessment of b 1 /b 2 and ADC 2 /ADC 1 improves the detection of clinically signiĮcant PCa, especially for PI-RADS 4 lesions. The b 1 /b 2 and ADC 2 /ADC 1 ratios are reliable cancer predictors for PI-RADS 4 and reduce diagnostic subjectivity. Using the proposed quantitative thresholds can support more informed decision-making regarding the need for biopsy in patients with equivocal MRI findings (PI-RADS 3 and 4).
- 23 December 2025
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 8 (4) , 60-71
Open AccessA New Perspective on the Role of MRI in Refining PI-RADS 3 and PI-RADS 4 Categories
Introduction : Prostate cancer (PCa) remains one of the leading causes of cancer-related mortality. Traditional diagnostic methods, including PSA testing and transrectal ultrasound (TRUS), have limitations in detecting early-stage PCa. MRI plays a key role in diagnosis, particularly in identifying clinically significant tumors. However, the PI-RADS v2.1 system has limitations in the quantitative assessment of pathological changes. Purpose : To develop and evaluate quantitative MRI criteria for the differential diagnosis of PI-RADS 3 and PI-RADS 4 lesions, and to identify statistically significant predictors of cancer presence in lesions. Materials and Methods : A retrospective analysis was conducted on 105 patients (aged 49–78 years, median age 65) with suspected PCa from 2019 to 2024. Patients were grouped based on clinical history: negative biopsy (34 %), elevated PSA and negative MRI dynamics (33 %), and rising PSA without ultrasound changes (32 %). Prostate MRI was performed using 1.5 T and 3 T scanners (bi-or multiparametric), with assessment according to PI-RADS v2.1. PI-RADS 4 lesions were identiĮed in 73.3 % of cases, and PI-RADS 3 lesions in 26.7 %. All patients underwent stereotactic MRI-targeted biopsy with sampling from target lesions and systematic biopsy. Statistical analysis included frequency tables, chi-square and Fisher͛ s tests, t-test, Mann–Whitney test, and ROC analysis. Results : PCa was conĮrmed in 78 % of cases (predominantly Gleason 7, ISUP grade 2 adenocarcinomas). PI-RADS 3–4 lesions were most often located in the peripheral zones (73.3 %, posterior regions). New quantitative parameters were introduced: the signal intensity ratio on high b-value DWI (b 1 /b 2 ) and on ADC maps (ADC 2 /ADC 1 ). For all lesions, a b1/b2 threshold х1.56 showed sensitivity of 81.7 % and speciĮcity of 91.3 %; ADC 2 /ADC 1 >2.65 showed 52.4 % sensitivity and 82.6 % speciĮcity. For PI-RADS 4 lesions, thresholds of b1/b2 >1.57 (87.1 % sensitivity, 85.7 % speciĮcity) and ADC2/ADC1 >2.2 (81.4 % and 85.7 %, respectively) were significant predictors of cancer. For PI-RADS 3 lesions, these ratios were not significant. Dynamic contrast enhancement (performed in 34.2 % of cases) helped to reĮne lesion localization but did not influence the biopsy decision; type 3 curves correlated with cancer in PI-RADS 4 lesions (95 %). Discussion : The introduction of quantitative criteria (b 1 /b 2 and ADC 2 /ADC 1 ) allows for a more objective assessment of PI-RADS 4 lesions, reducing the dependence on radiologist experience. These parameters are signiĮcant predictors of clinically significant PCa, particularly in PI-RADS 4. Further research is needed to identify reliable quantitative markers for PI-RADS 3 lesions. Biparametric MRI (without contrast) was suĸcient for biopsy decision-making in most cases (65.7 %), making the method more accessible and safer. Quantitative analysis may assist in selecting between bi- and multiparametric MRI protocols. Conclusion : MRI with quantitative assessment of b 1 /b 2 and ADC 2 /ADC 1 improves the detection of clinically signiĮcant PCa, especially for PI-RADS 4 lesions. The b 1 /b 2 and ADC 2 /ADC 1 ratios are reliable cancer predictors for PI-RADS 4 and reduce diagnostic subjectivity. Using the proposed quantitative thresholds can support more informed decision-making regarding the need for biopsy in patients with equivocal MRI findings (PI-RADS 3 and 4).